Russia registers one-shot Sputnik Light for use against Covid: Report

Russia said last week that it had completed clinical trials for the slimmed-down vaccine

Sputnik
A medical worker prepares to administer the Russian Sputnik V coronavirus disease (COVID-19) vaccine in the Republic of San Marino (Photo: Reuters)
Reuters
1 min read Last Updated : Mar 29 2021 | 6:23 PM IST
Russia's health ministry has registered the one-shot Sputnik-Light version of its COVID-19 vaccine for use, the TASS news agency reported on Monday.

Russia said last week that it had completed clinical trials for the slimmed-down vaccine, which it has cast as a possible temporary solution to help countries with high infection rates make the vaccine go further.

Moscow has said that its two-dose Sputnik V vaccine will remain the main version used in Russia.

Earlier on Monday, Russia's RDIF sovereign wealth fund and China's Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia's Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.

RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccine

Next Story